首页 | 本学科首页   官方微博 | 高级检索  
     

重组人血管内皮抑制素联合化疗治疗晚期肺腺癌患者的疗效及安全性
引用本文:袁亮,胡勇.重组人血管内皮抑制素联合化疗治疗晚期肺腺癌患者的疗效及安全性[J].检验医学与临床,2021,18(2):186-188,193.
作者姓名:袁亮  胡勇
作者单位:陕西省汉中市中心医院肿瘤内科,陕西汉中 723000;陕西省汉中市中心医院放疗科,陕西汉中 723000
摘    要:目的 探讨重组人血管内皮抑制素联合化疗(培美曲塞+顺铂)治疗晚期肺腺癌的临床疗效,以及患者血清肿瘤标志物的变化及不良反应发生情况.方法 选取汉中市中心医院肿瘤内科2017年1月至2019年1月收治的76例驱动基因阴性的晚期肺腺癌患者作为研究对象,36例对照组患者单纯采用化疗(培美曲塞+顺铂)进行治疗,40例试验组患者采...

关 键 词:重组人血管内皮抑制素  化疗  肺腺癌  安全性

Efficacy and safety evaluation of endostar combined with chemotherapy for treatmentin patients with advanced lung adenocarcinoma
YUAN Liang,HU Yong.Efficacy and safety evaluation of endostar combined with chemotherapy for treatmentin patients with advanced lung adenocarcinoma[J].Laboratory Medicine and Clinic,2021,18(2):186-188,193.
Authors:YUAN Liang  HU Yong
Affiliation:(Department of Medical Oncology,Hanzhong Central Hospital,Hanzhong,Shaanxi 723000,China;Department of Radiation Oncology,Hanzhong Central Hospital,Hanzhong,Shaanxi 723000,China)
Abstract:Objective To explore the clinical efficacy,the changes of tumor markers and adverse reactions of endostar combined with chemotherapy(Pemetrexed Disodium+Cisplatin)for treatment in patients with advanced lung adenocarcinoma.Methods A total of 76 patients with advanced lung adenocarcinoma who were treated in department of medical oncology of Hanzhong Central Hospital from January 2017 to January 2019 were enrolled in the study.Totally 36 patients in the control group who only accepted chemotherapy(Pemetrexed Disodium+Cisplatin),and 40 patients in the experimental group were treated with endostar combined with chemotherapy.The clinical efficacyobjective remission rate(ORR)and disease control rate(DCR)]and progression-free survival(PFS),serum tumor marker levels after treatment and adverse reactions were compared between the two groups.Results The ORR and DCR of experimental group were 50.0%and 87.5%,the ORR and DCR of control group were 27.8%and 66.7%,differences between the two groups were statistically significant(χ^2=3.916 and 4.736,P<0.05).The PFS of experimental group was(7.537±0.334)months,which was higher than that of control group(5.535±0.373)months],the difference between the two groups was statistically significant(t=14.187,P<0.05).The levels of serum carbohydrate antigen 125(CA125),cytokeratin 19 fragment(CYFRA21-1)and carcinoembryonic antigen(CEA)after treatment of experimental group were significantly lower than those of the control group(P<0.05).The adverse reactions between the two groups had no statistically significance(P>0.05).Conclusion Endostar combined with chemotherapy for treatment in patients with advanced lung adenocarcinoma has good effect,which could significantly prolong the PFS,reduce the levels of serum tumor markers,as well as has better safety,which is worthy of promotion.
Keywords:endostar  chemotherapy  lung adenocarcinoma  safety
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号